Factor XIII in scleroderma: in vitro studies.
The administration of Factor XIII (FXIII) produces a beneficial effect on the skin lesions in about 50% of the treated patients with progressive systemic sclerosis (PSS). The effect of FXIII on various skin fibroblast functions (proliferation, attachment, biosynthetic activity and mechanical properties) was investigated in vitro using normal and PSS strains. In cell culture, most of the PSS fibroblast strains synthesized excessive amounts of collagen. Other cell functions such as adhesion to collagen I or III, to fibronectin, retraction of collagen lattices, proliferation in low serum concentration and degradation of newly synthesized collagen were not significantly different. The addition of FXIII (I U/ml) inhibited the synthesis of collagen by normal fibroblasts and reduced it in PSS fibroblasts to a level similar to that of normal fibroblasts. This effect was observed for cells cultured on plastic or in a collagen lattice. In the latter, an increased amount of collagen degradation was observed. No significant effect of FXIII on the other cell functions was noted. Excessive collagen production by PSS fibroblasts can be repressed by FXIII in vitro by at least two distinct mechanisms: a reduction of collagen synthesis and an increased degradation of the newly synthesized collagen.
Paye
M
M
Laboratory of Experimental Dermatology, Tour de Pathologie, CHU du Sart Tilman, University of Liège, Belgium.
Read
D
D
Nusgens
B
B
Lapiere
C M
CM
D000328:Adult; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D003094:Collagen / Q000096:biosynthesis; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008297:Male; D014176:Protein Biosynthesis; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000378:metabolism*; D012867:Skin / Q000378:metabolism; D011503:Transglutaminases / Q000378:metabolism* / Q000627:therapeutic use
D003094:Collagen; D011503:Transglutaminases